Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Inclusion Criteria: * Men or women ≥ 18 and ≤ 80 years old * Diagnosis of multiple myeloma: * Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval * ≥ 200 mg of monoclonal protein in the urine on 24 hour electrophoresis * Serum free light chain ≥ 100 mg/L (10 mg/dL) and abnormal serum free kappa to serum free kappa light chain ratio * Previously treated relapsed and refractory multiple myeloma * Patients must have received at least one prior line of therapy; * Prior therapy must include at least 2 cycles of lenalidomide and at least 2 cycles of a proteasome inhibitor (either in separate regimens or within the same regimen) * Disease progression on or within 60 days of completion of last therapy. * ANC ≥ 1000/μL. * G-CSF is not permitted within 14 days of screening. * Patients with ANC \<1000/µL can be considered for screening on a case by case basis with additional monitoring, after discussion with and approval from the PI. * Platelet count ≥ 50,000/µL. Platelet transfusion is not permitted within 7 days of screening. * Hemoglobin ≥ 8 g/dL. Red blood cell transfusions are permitted to meet eligibility criteria. * Calculated creatinine clearance of ≥ 30 mL/min by Cockcroft-Gault equation. * Patient has adequate hepatic function, as evidenced by each of the following: * Serum bilirubin values \< 2 mg/dL; and * Serum aspartate transaminase (ALT) and/or aspartate…